A man aged in his 60′s was admitted to Kobe Rosai Hospital, Kobe, Japan, because of impaired consciousness. One week before admission, he manifested erythema on his trunk and extremities that was associated neither with fever nor with flulike symptoms. Thirst and nausea developed within a few days of erythema onset. Whereas the erythema disappeared spontaneously, the thirst and nausea worsened. A family member noticed abnormal behavior of the patient and took him to the emergency room of the hospital, where his consciousness was found to be impaired. He manif-ested ketonuria and metabolic acidosis with marked hyperglycemia, a slightly increased hemoglobin A1c content (National Glycohemoglobin Standardization Program value calculated from the Japan Diabetes Society value,1) and a low serum C-peptide level (Table 1). His hemoglobin A1c at an annual health check-up carried out 17 days previously was 5.5%. Serum levels of amylase and lipase were high, and liver and kidney function were slightly and severely attenuated, respectively. Computed tomography showed no morphological abnormalities of abdominal organs including the pancreas. The patient was immediately admitted to the hospital, and treated according to standard care for diabetic ketoacidosis by intravenous supplementation with electrolyte fluid and insulin. His consciousness returned to normal as the hyperglycemia and acidosis were ameliorated. On the day of admission, the serum titer of antibodies to glutamic acid decarboxylase was borderline high, but it had returned to a normal level on a second test carried out 2 weeks later. Tests for islet cell antibodies and antibodies to anti-insulinoma-associated protein-2 antibody were negative. Human Leukocyte antigen typing revealed the patient to harbor DRB1*09:01-DQB1*03:03 and DRB1*04:05-DQB1*04:01alleles, the latter of which confers susceptibility to fulminant type 1 diabetes mellitus2. The patient was diagnosed with fulminant type 1 diabetes mellitus and discharged 36 days after admission with multiple daily subcutaneous insulin injections. We examined antibody titers for various viruses in serum obtained on the first and 21st days of hospitalization (Table S1). Among those examined, only immunoglobulin M class antibodies to parvovirus B19 changed substantially during the first 3 weeks of hospitalization, decreasing from 1.32 (normal range <0.8) to 0.96, suggestive of a recent infection with parvovirus B19. Given that erythema is a common clinical manifestation of parvovirus B19 infection3, the skin rash experienced by the present patient 1 week before admission might have been caused by infection with the virus. It is of note that parvovirus B19 infection is known to trigger a variety of autoimmune disease-like conditions including systemic lupus erythematosus, rheumatoid arthritis and autoimmune cytopenia3. Similarity in amino acid sequence between parvovirus B19 proteins and human proteins thought to be related to such diseases has been implicated in the pathogenesis of autoimmune disorders triggered by this virus3. Although the pathophysiology of fulminant type 1 diabetes mellitus remains unclear, immunologic processes triggered by viral infection have been implicated4. Further accumulation of clinical evidence for the association of viral infection with fulminant type 1 diabetes mellitus together with basic studies of the mechanistic link between viral infection and β-cell destruction should provide further insight into the pathogenesis of this condition. The authors declare no conflict of interest. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Read full abstract
Dec 1, 2015
Crisinel Pa + 4
Open Access
